{"cluster": 16, "subcluster": 1, "abstract_summ": "RESULTS: Preclinical studies have reported that angiotensin receptor blockers (ARBs) and ACE inhibitors might increase ACE2 expression in several cell types.Based upon such evidences, the review demonstrated possible therapeutic interventions, targeting both the protective and deleterious effects of ACE2 in COVID-19 disease, primarily inhibiting ACE2-virus interactions or administering soluble ACE2.The possible upregulation in ACE2 receptor expression may predispose individuals with aberrant RAS status to higher viral load on infection and relatively more cell loss.In the present study we analyze the epidemiologic data of COVID-19 of Tibet and high-altitude regions of Bolivia and Ecuador, and compare to lowland data, to test the hypothesis that high-altitude inhabitants (+2500 m above sea-level) are less susceptible to develop severe adverse effect in acute SARS-CoV-2 virus infection.The identification of angiotensin-converting-enzyme 2 (ACE2) as the receptor allowing viral entry to cells precipitated our interest in the role of ACE2 in COVID-19 pathogenesis.", "title_summ": "COVID-19 as a Viral Functional ACE2 Deficiency Disorder with ACE2 Related Multi-organ DiseaseThe dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutionsIs the kidney a target of SARS-CoV-2?Does the pathogenesis of SAR-CoV-2 virus decrease at high-altitude?SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implicationsSARS-CoV-2 infection and glucose homeostasis in pregnancy.What about antenatal corticosteroids?COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvementSARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary ReviewCoronavirus SARS-Cov-2 and arterial hypertension - facts and myths.", "title_abstract_phrases": "RESULTS: Preclinical studies have reported that angiotensin receptor blockers (ARBs) and ACE inhibitors might increase ACE2 expression in several cell types.The possible upregulation in ACE2 receptor expression may predispose individuals with aberrant RAS status to higher viral load on infection and relatively more cell loss.Potential underlying mechanisms such as: (i) a compromised half-live of the virus caused by the high-altitude environment, and (ii) a hypoxia mediated down regulation of angiotensin-converting enzyme 2 (ACE2), which is the main binding target of SARS-CoV-2 virus in the pulmonary epithelia are discussed.Based upon such evidences, the review demonstrated possible therapeutic interventions, targeting both the protective and deleterious effects of ACE2 in COVID-19 disease, primarily inhibiting ACE2-virus interactions or administering soluble ACE2.The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutionsThe novel corona virus disease has shaken the entire world with its deadly effects and rapid transmission rates, posing a significant challenge to the healthcare authorities to develop suitable therapeutic solution to save lives on earth."}